In the Asia Pacific region, Sarclisa combination regimens were also recently approved by the National Medical Products Administration in China, specifically Sarclisa-VRd in NDMM patients who are ...
In the Asia-Pacific region, Japan is currently reviewing a regulatory submission for the antibody in NDMM subjects who are not eligible for haematopoietic stem cell transplantation. Sarclisa has ...